Shanghai Henlius Biotech, Inc. (“Henlius”) announced this week that it has entered into a license and collaboration agreement with Eurofarma Laboratórios SA (“Eurofarma”), a Brazilian multinational biopharmaceutical company, for the development, manufacturing and commercialization of three biosimilar products in 16 Latin American countries. The three products are HANLIKANG^® (rituximab), HANQUYOU^® (trastuzumab), and HANBEITAI^® (bevacizumab).  Under the agreement terms, Henlius will receive up to a total of $50.5 million, including a $4.5 million upfront payment.  Eurofarma will acquire exclusive rights to HANLIKANG^® (rituximab) in 12 countries, as well as HANQUYOU^® (trastuzumab) in 11 countries and HANBEITAI^® (bevacizumab) in 15 countries.  In addition, Eurofarma will obtain semi-exclusive rights to the three products in Brazil.

[View source.]